Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017

References

• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28. doi:10.1056/NEJM200106213442507.
   PubMed Web of Science ®Google Scholar
• Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588–98. doi:10.1056/NEJMoa0804877.
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5):127–32. doi:10.1067/S0022-3476(03)00510-9.
   PubMed Web of Science ®Google Scholar
• Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial virus seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep. 2018;67(2):71–76. doi:10.15585/mmwr.mm6702a4.
   PubMed Web of Science ®Google Scholar
• Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137(6):865–70. doi:10.1067/mpd.2000.110531.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UDL, Silvestri M, Pistorio A, Chezzi C. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007;166(12):1267–72. doi:10.1007/s00431-007-0418-y.
   PubMed Web of Science ®Google Scholar
• Straňák Z, Saliba E, Kosma P, Posfay-Barbe K, Yunis K, Farstad T, Unnebrink K, van Wyk J, Wegzyn C, Notario G, et al. Predictors of RSV LRTI hospitalization in infants born at 33 to 35 weeks gestational age: A large multinational study (PONI). PLoS One. 2016;11(6):e0157446. doi:10.1371/journal.pone.0157446.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Noor A Respiratory syncytial virus infection treatment and management. WebMD, LLC; 2019 Feb 25 [accessed 2020 Mar 17]. https://emedicine.medscape.com/article/971488-treatment.
   Google Scholar
• IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3 Pt 1):531–37. doi:10.1542/peds.102.3.531.
   Web of Science ®Google Scholar
• Synagis [package insert]. Gaithersburg (MD): MedImmune LLC; 2017.
   Google Scholar
• Anderson EJ, Carosone-Link P, Yogev R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk infants and children: A propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699–704. doi:10.1097/INF.0000000000001533.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102(5):1211–16. doi:10.1542/peds.102.5.1211.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694–701. doi:10.1542/peds.2009-2345.
   PubMed Web of Science ®Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–20. doi:10.1542/peds.2014-1665.
   PubMedGoogle Scholar
• American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Red book: 2012 report of the committee on infectious diseases. Elk Grove Village (IL): American Academy of Pediatrics; 2012. p. 609–18.
   Google Scholar
• American Academy of Pediatrics Committee on Infectious Diseases. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003;112(6 Pt 1):1442–46. doi:10.1542/peds.112.6.1442.
   PubMedGoogle Scholar
• Ralston SL, Lieberthal AS, Me issnerHC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. doi:10.1542/peds.2014-2742.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Krilov LR, DeVincenzo JP, Checchia P, Halasa N, Simões E, Domachowske J, Forbes M, Pannaraj P, McBride S, et al. SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among US infants born at 29 to 35 weeks’ gestational age not receiving immunoprophylaxis. Am J Perinatol. 2017;34(1):51–61. doi:10.1055/s-0036-1584147.
   PubMed Web of Science ®Google Scholar
• Krilov LR, Fergie J, Goldstein M, Brannman L. Impact of the 2014 American academy of pediatrics immunoprophylaxis policy on the rate, severity, and cost of respiratory syncytial virus hospitalizations among preterm infants. Am J Perinatol. 2020;37(2):174–83. doi:10.1055/s-0039-1694008.
   PubMed Web of Science ®Google Scholar
• Kong AM, Krilov LR, Fergie J, Goldstein M, Diakun D, Wade S, Pavilack M, McLaurin K. The 2014-2015 national impact of the 2014 American academy of pediatrics guidance for respiratory syncytial virus immunoprophylaxis on preterm infants born in the United States. Am J Perinatol. 2018;35(2):192–200. doi:10.1055/s-0037-1606352.
   PubMed Web of Science ®Google Scholar
• Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr. 2017;181:183–188.e1. doi:10.1016/j.jpeds.2016.10.074.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, et al. SENTINEL1: two-season study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks‘ gestational age not receiving immunoprophylaxis. Am J Perinatol. 2020;37(4):421–29. doi:10.1055/s-0039-1681014.
   PubMed Web of Science ®Google Scholar
• Goldstein M, Krilov LR, Fergie J, McLaurin K, Wade S, Diakun D, Lenhart G, Bloomfield A, Kong A. Respiratory syncytial virus hospitalizations among U.S. preterm infants compared with term infants before and after the 2014 American Academy of Pediatrics guidance on immunoprophylaxis: 2012–2016. Am J Perinatol. 2018;35(14):1433–42. doi:10.1055/s-0038-1660466.
   PubMed Web of Science ®Google Scholar
• US Bureau of Labor Statistics. Consumer price index detailed reports, annual average 2017. 2018 [accessed 2020 Mar 17] https://www.bls.gov/cpi/tables/home.htm.
   Google Scholar
• Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA. 2014;312(22):2401–02. doi:10.1001/jama.2014.16153.
   PubMed Web of Science ®Google Scholar
• Belleudi V, Trotta F, Pinnarelli L, Davoli M, Addis A. Neonatal outcomes following new reimbursement limitations on palivizumab in Italy. Arch Dis Child. 2018;103(12):1163–67. doi:10.1136/archdischild-2018-315349.
   PubMed Web of Science ®Google Scholar
• Grindeland CJ, Mauriello CT, Leedahl DD, Richter LM, Meyer AC. Association between updated guideline-based palivizumab administration and hospitalizations for respiratory syncytial virus infections. Pediatr Infect Dis J. 2016;35(7):728–32. doi:10.1097/INF.0000000000001150.
   PubMed Web of Science ®Google Scholar
• Capizzi A, Silvestri M, Orsi A, Cutrera R, Rossi GA, Sacco O. The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence. Ital J Pediatr. 2017;43(1):71. doi:10.1186/s13052-017-0390-8.
   PubMedGoogle Scholar
• Zuccotti G, Fabiano V. Indications to respiratory syncytial virus immunoprophylaxis in the 29-32 wGA group: is there still room for debating? Ital J Pediatr. 2017;43(1):17. doi:10.1186/s13052-017-0341-4.
   PubMedGoogle Scholar